Project Grant HT94252510473

This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,556,809.00 to the University of Washington to develop a vaccine to prevent colorectal cancer. The award, which began on June 15, 2024 and is scheduled for completion by June 14, 2027, supports innovative biomedical research aimed at improving health outcomes for military service members, veterans, and the broader public. As a sub-award under this...

The federal Project Grant award of $1,214,375.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), is funding a research project led by Yale University. The project is investigating the use of decoy-resistant IL-18 and immune checkpoint inhibitors in preclinical murine and ex vivo patient-derived models of renal cell carcinoma. The award began on September 15, 2024 and is set to conclude on September 14, 2028. The Military Medical Research...

This federal Project Grant award of $400,000.00 was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, with a performance period from October 1, 2024 to September 30, 2026. The award supports research by the University of Maryland, Baltimore to develop "drug conjugates of modified LGR4/5/6 ligands for cancer treatment." The university, as the prime awardee, has extensive expertise in biomedical research, clinical trials, and...

This federal Project Grant award of $1,622,612.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports preclinical validation of novel combination therapeutic strategies targeting KRAS and BRAF mutated colorectal cancer. The award was granted to The University of Texas M.D. Anderson Cancer Center to conduct this advanced biomedical research, with the goal of enabling near-term clinical examination of the developed therapies. The 3-year project...

The Department of Defense (DoD) Defense Health Agency has awarded a $677,998 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to Weill Medical College of Cornell University. The grant, titled "TARGETING ECDNA TO REVERSE THERAPY-RESISTANCE IN UROTHELIAL CANCER", will support advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The project will focus on investigating medical...

The federal Project Grant award, valued at $176,000.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports the Sloan-Kettering Institute for Cancer Research in establishing a mouse model of myxoid/round cell liposarcoma with endogenous translocations. This research aims to transform healthcare for military service members, veterans, and the broader public by advancing biomedical research on critical health...

The federal Project Grant award, valued at $1,690,396.00 and issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports epigenetic research on BRAF-mutant colorectal cancers at The University of Texas MD Anderson Cancer Center. The research aims to investigate the epigenetic mechanisms and targeting approaches during the response to BRAF inhibitor and anti-EGFR therapy for BRAF-mutant colorectal cancers. The award period runs from...

The federal Project Grant award in the amount of $499,999.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), funds research by the Institute of Cancer Research: Royal Cancer Hospital (The) to study the interplay of molecular and spatial architectures with clinical states in prostate cancer. The research project aims to make discoveries that defeat cancer through innovative biomedical research. As a subawardee, the Institute of...

The Defense Health Agency awarded a $1,116,955 Project Grant to The Broad Institute, Inc. to identify new therapies and therapeutic targets in gastroesophageal cancer. This 3-year grant, running from August 15, 2023 to August 14, 2026, is funded through the Military Medical Research and Development program (CFDA 12.420). The Broad Institute, a non-profit biomedical and genomic research organization, will leverage its expertise in areas like genomic sequencing, data analysis, and translational...

This federal Project Grant award of $613,125.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by the University of Texas MD Anderson Cancer Center to develop EGFRXHER3 bispecific CAR-T cells for targeting EGFR tyrosine kinase inhibitor drug-tolerant persister cells. The research aims to transform healthcare for military service members, veterans, and the broader public by advancing innovative...